CoAxia’s NeuroFlo Catheter For Stroke Shot Down By Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Neurological Devices panel found that the benefits of the catheter system do not outweigh the risks for the intended expanded use to treat acute ischemic stroke, and that further studies are needed.
You may also be interested in...
Zoll Acquires CoAxia Assets In Bid To Revive NeuroFlo Stroke Catheter
CoAxia Inc. did not have the funds to continue after its de novo petition for the NeuroFlo catheter was rejected by FDA for acute ischemic stroke. But Zoll still sees opportunity for the device; now that it owns the technology, the firm plans to design a new pivotal trial to take before the agency.
CoAxia On Last Legs Following Contested FDA Panel Meeting
CoAxia is out of money in the wake of an unfavorable neurological devices panel meeting about its de novo application for expanded use of its NeuroFlo catheter. The firm says FDA mishandled the meeting, the first public panel meeting for a de novo submission.
Regulatory News In Brief
International draft guidance on a single-audit program for device facilities is expected out by the end of the month, ECRI weighs in on UDI proposed rule, and more regulatory updates.